Skip to main content
Figure 2 | Arthritis Research & Therapy

Figure 2

From: B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

Figure 2

(a) IL-6 and (b) BAFF levels at baseline and during follow up. IL-6 and B-cell activating factor (BAFF) levels evaluated in nine patients treated with anti-CD20 at baseline and during the follow up. (a and b) Each line represents the modification of IL-6 and BAFF parameters in each patient during the follow up. Each symbol (on the right) represents one patient and corresponds to the number of the patient of Table 3.

Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us